Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report

Osimertinib is commonly used in pulmonary adenocarcinoma patients who are resistant to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and carry the T790M mutation. However, the use of osimertinib may result in the development of further resistance, most commonly...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jing, Zou, Ming, Lv, Jinyan, Han, Yingmin, Wang, Guangzhi, Wang, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134962/
https://www.ncbi.nlm.nih.gov/pubmed/30233215
http://dx.doi.org/10.2147/OTT.S170358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134962/
https://www.ncbi.nlm.nih.gov/pubmed/30233215
http://dx.doi.org/10.2147/OTT.S170358

Ejemplares similares